SCHEMBL6411682

SCHEMBL6411682

Cc1ccc(CNC(=O)C2c3ccccc3C(=O)NC2c2cc(C(F)(F)F)cc(C(F)(F)F)c2)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 11/20 0.47
ALDH1A1 P00352 5/20 0.47
MAPT P10636 5/20 0.47
TSHR P16473 3/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
USP2 O75604 1/20 0.47
ALOX15 P16050 1/20 0.47
CYP2C19 P33261 4/20 0.37
CYP1A2 P05177 3/20 0.37
TACR1 P25103 1/20 0.35
HPGD P15428 5/20 0.34
CYP3A4 P08684 4/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP2D6 P10635 1/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CYP2C9 P11712 2/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6412811 0.85 NPC1 (0.47) PKMALDH1A1MAPTTSHRNPC1
SCHEMBL6418985 0.84 TACR1 (0.44) ALDH1A1NPC1TACR1MEN1KMT2A
SCHEMBL6413414 0.81 POLB (0.38) PKMALDH1A1MAPTTSHRKDM4E
SCHEMBL6420424 0.81 TSHR (0.63) PKMALDH1A1MAPTTSHRKDM4E
SCHEMBL6414378 0.81 CYP2C19 (0.41) CYP2C19TACR1
SCHEMBL6412312 0.81 TACR1 (0.39) TSHRTACR1MEN1KMT2AHTT
SCHEMBL6417317 0.80 MAPT (0.47) ALDH1A1MAPTTSHRKDM4EALOX15
SCHEMBL6415621 0.79 P2RX7 (0.39) CYP2C19TACR1
SCHEMBL6410861 0.76 TACR1 (0.38) ALDH1A1TACR1MEN1KMT2A
SCHEMBL6410860 0.76 TACR1 (0.38) ALDH1A1TACR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD PKM 3928/4885ALDH1A1 1368/4885MAPT 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.